Category: General Prostate

Reviews and ratings are very important in today’s world. Look at the internet. Whether it’s Yelp, Amazon, Ebay, Angie’s List or hundreds more, the number of stars or thumbs up are not as influential as the qualitative comments left by consumers. In similar fashion, radical prostatectomy is... keep reading

It is always thrilling when a treatment is working so well in a clinical trial that the study ends early and the FDA moves rapidly with approval. This was the case with a clinical study called ALSYMPCA (Alpharadin in Symptomatic Prostate Cancer Patients). keep reading

As a treatment for prostate cancer, prostatectomy (surgical gland removal) continues to be dogged by positive surgical margins. Patients who have PSMs are at higher risk for recurrence. The issue is not the surgical approach... keep reading

Let’s start with cells. Animals, including humans, are made up of millions, billions, or even (in the case of humans) trillions of cells. We know from basic biology that cells grow and divide, and in the process each new cell contains a copy of its entire genome. However... keep reading

Thanks to PSA screening and early detection, most prostate cancer is diagnosed while it is still contained in the prostate gland. This implies favorable odds that any whole-gland treatment is potentially curative... keep reading

I have written several blogs on external beam radiation for prostate cancer along with its side effects. Radiation is a good choice for the right patient. As with all prostate cancer treatments, it is essential to match a treatment with an individual’s cancer because many factors go into the choice... keep reading

What do these three things have in common: Benign prostatic hyperplasia or BPH (non-cancerous prostate enlargement),male pattern baldness and aggressive prostate cancer that is potentially lethal? The first—and most obvious—answer is that they are all risks that men face with aging. The second less obvious answer is... keep reading

A PSMA PET/CT scan (or simply PSMA PET) like the one described below that incorporates the radioisotope Gallium-68, is the most sensitive method to detect metastatic prostate cancer (mPCa). PSMA PET has thus quickly gained wide use, including evaluating how well a patient’s mPCa is responding to therapy... keep reading

An exciting new imaging modality called PSMA PET/CT has entered the global prostate cancer diagnosis scene. When a short-lived positron emitting isotope called Gallium 68 is bonded to a molecule that is attractive to a specific protein found abundantly on the surface of prostate cancer (PCa) cells, the cells “light up” on PET/CT scans. keep reading

Urologist Bert Vorstman MD continues to be “a keen observer of the state of prostate cancer.” 1 During an interview for the American Society of Clinical Oncology (ASCO), he made some observations in which he did not mince words... keep reading